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ARC-520 Results in Prolonged Hepatitis 
B Surface Antigen Response in Patients 
With Chronic Hepatitis B Infection
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BaCKgRoUND aND aIMS: ARC-520, the first an RNA 
interference (RNAi) therapeutic, was designed to reduce all 
RNA transcripts derived from covalently closed circular DNA, 
leading to a reduction in viral antigens and hepatitis B virus 
(HBV) DNA.
appRoaCH aND ReSUltS: We aimed to evaluate the 
depth of hepatitis B surface antigen (HBsAg) decline in re-
sponse to multiple doses of ARC-520 compared to placebo 
(PBO) in two randomized, multicenter studies in nucleoside/
nucleotide analogue reverse-transcriptase inhibitor (NUC)– 
experienced patients with hepatitis B early antigen (HBeAg)–
negative (E-neg) or HBeAg-positive (E-pos) disease. A total 
of 58 E-neg and 32 E-pos patients were enrolled and re-
ceived four monthly doses of PBO (n  =  20 E-neg, 11 
E-pos), 1  mg/kg ARC-520 (n  =  17 E-neg, 10 E-pos), or 
2  mg/kg ARC-520 (n  =  21 E-neg, 11 E-pos) concomitantly 
with NUC. HBsAg change from baseline to 30 days after 
the last ARC-520 dose were compared to PBO. Both E-neg 
and E-pos high-dose groups significantly reduced HBsAg 
compared to PBO, with mean reductions of 0.38 and 0.54 
log IU/mL, respectively. HBsAg reductions persisted for ap-
proximately 85 days and >85 days after the last dose in 
E-neg and E-pos patients, respectively. The low-dose groups 
did not reach statistical significance in either study. E-pos 
patients showed a dose-dependent reduction in HBeAg from 
baseline. Mean maximum reduction was 0.23 and 0.69 log 
Paul Ehrlich IUs/mL in the low-dose and high dose ARC-
520 groups respectively. ARC-520 was well tolerated, with 
only two serious adverse events of pyrexia possibly related to 
study drug observed.
CoNClUSIoNS: ARC-520 was active in both E-neg and 
E-pos, NUC-experienced HBV patients; but absolute HBsAg 
reductions were moderate, possibly due to expression of 
HBsAg from integrated HBV DNA, indicating the need for 
RNAi therapeutics that can target viral transcripts regardless 
of origin. (Hepatology 2020;72:19-31).
Infection with hepatitis B virus (HBV) is a signif-icant global health problem. The World Health Organization reports that an estimated 257 mil-
lion people worldwide are chronically infected with 
HBV.(1) It is estimated that during their lifetimes 
15%-40% of chronic HBV (CHB) patients may 
develop serious sequelae of infection such as chronic 
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hepatitis, fibrosis, cirrhosis, and hepatocellular car-
cinoma (HCC).(2-5) Functional cure characterized 
by a sustained loss of hepatitis B surface antigen 
(HBsAg) with or without antibody seroconversion has 
emerged as a consensus endpoint for new therapies 
for CHB.(4,6) Current therapies for CHB, although 
effective at suppressing viral DNA and reducing liver 
inflammation, rarely result in sustained functional 
cures off therapy. Multiple studies have highlighted 
the importance of viral load in predicting the risk of 
cirrhosis and HCC.(7,8) However, sustained HBsAg 
loss has been identified as an additional, independent 
predictor of further reductions in the risk of HCC 
development.(9-11)
HBV persists in the nucleus of hepatocytes as a 
minichromosome, covalently closed circular DNA 
(cccDNA), which serves as the template for five overlap-
ping viral transcripts including pregenomic RNA.(12,13) 
All HBV transcripts are encoded in overlapping read-
ing frames, with a common 3′ end, and use the same 
polyadenylation signal (PAS). These transcripts serve 
as templates for the translation of all viral proteins, 
i.e., precore (HBV early antigen [HBeAg]); core; 
polymerase; L, M, and S surface antigens (collectively 
HBsAg); and X protein. These viral proteins play an 
important role in the production of new viral particles 
and the viral life cycle; however, HBeAg and HBsAg 
are often produced at large excess, and both can be 
detected at high levels in the liver and serum of many 
patients. HBeAg and HBsAg have been implicated in 
the maintenance of viral infection through induction 
of exhaustion or impairment of cluster of differenti-
ation 8–positive T-cell immune responses.(14,15) More 
recently, a single-dose study with ARC-520 in patients 
with CHB combined with studies in chimpanzees 
chronically infected with HBV showed that HBsAg 
was expressed not only from the episomal cccDNA 
minichromosome but also from transcripts arising from 
HBV DNA integrated into the host genome and was 
the dominant source of HBsAg in HBeAg-negative 
(E-neg) or nucleos(t)ide analogue reverse-transcriptase 
inhibitor (NUC)–experienced patients.(16)
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Because high antigen load is believed to play a key 
role in maintaining chronic viral infection, there is 
interest in new therapies that can reduce both viral 
loads and antigens as a means to restore immune con-
trol of the infection. Therapies using RNA interfer-
ence (RNAi) as a mechanism of action can directly 
target HBV mRNA transcripts with high specificity, 
profoundly reducing the production of viral proteins, 
including HBsAg. RNAi utilizes small, noncoding 
RNAs to regulate the expression of genetic infor-
mation.(17) ARC-520 injection was the first RNAi-
based therapeutic to enter the clinic. It consists of 
two synthetic short interfering RNAs (siRNAs) con-
jugated to cholesterol, which enhances delivery of 
the siRNAs to hepatocytes. ARC-520 injection uses 
a polymer-based excipient (ARC-EX1) that enables 
endosomal escape of the siRNAs into the cytoplasm 
where RNAi occurs.(18) The mRNA target sites for 
ARC-520 are located 118 and 71 bases upstream, 
respectively, of the conventional HBV PAS, within the 
open reading frame of the HBV X protein. Because 
all cccDNA-derived HBV transcripts overlap in this 
region, the siRNAs in ARC-520 could target for deg-
radation all cccDNA-derived viral transcripts, thus 
preventing translation of all cccDNA-derived viral 
proteins. They are, however, not expected to cleave 
most transcripts resulting from integrated HBV DNA 
due to loss of the target site located in the DR1/DR2 
region of the virus, which is commonly deleted upon 
HBV integration.(16)
We have previously reported on the safety, tolera-
bility, and pharmacokinetics of ARC-520 in healthy 
volunteers(19) as well as single-dose pharmacodynam-
ics of ARC-520 in a phase 2 study in patients with 
CHB.(16) Here, we report on two double-blinded, 
phase 2 multidose studies of ARC-520 in NUC-
experienced, E-neg, or HBeAg-positive (E-pos) 
patients with CHB in combination with tenofovir 
(TDF) or entecavir (ETV).
Participants and Methods
StUDy DeSIgN
Two multicenter, randomized, double-blind, placebo- 
controlled, multidose, phase 2 studies were conducted 
in parallel to evaluate the level of HBsAg reduction fol-
lowing intravenous administration of the investigational 
product ARC-520 injection to a population of adults 
with CHB infection. The two studies were similar in 
design, with the difference being that one study was 
conducted in E-neg patients (the Heparc-2002 study, 
Clini caltr ials.gov registration no. NCT02604199), and 
the other study was conducted in E-pos patients (the 
Heparc-2003 study, Clini caltr ials.gov registration no. 
NCT02604212). For Heparc-2002 and Heparc-2003 
it was planned to enroll 60 patients and 48 patients, 
respectively, into four treatment groups at a 1:1:2:2 
ratio (placebo [PBO] low dose plus ETV or TDF, 
PBO high dose plus ETV or TDF, 1 mg/kg ARC-520 
plus ETV or TDF, 2  mg/kg ARC-520 plus ETV or 
TDF, respectively). Patients who had signed an insti-
tutional review board/independent ethics committee 
approved informed consent and had met all the proto-
col eligibility criteria were randomized to a treatment 
by a centralized, electronic system. Blinding to treat-
ment assignment was maintained throughout the study 
period. The studies were conducted at multiple sites 
in Hong Kong, the Republic of Korea, and Germany, 
with recruitment of subjects starting in November 
2015, early termination of study in November 2016, 
and last patient visit in December 2016. The studies 
were terminated early due to monkey deaths occurring 
in a nonclinical study with another RNAi investiga-
tional product and attributed to the ARC-EX1 deliv-
ery agent also used in ARC-520. This toxicity was not 
associated with the siRNA used in ARC-520.
Eligible patients were to be enrolled in parallel 
into one of four treatment groups: low-dose PBO 
(n  =  10 for Heparc-2002, n  =  8 for Heparc-2003), 
high-dose PBO (n  =  10 for Heparc-2002, n  =  8 for 
Heparc-2003), low-dose ARC-520 injection (1 mg/kg, 
n = 20 for Heparc-2002, n = 16 for Heparc-2003), or 
high-dose ARC-520 injection (2  mg/kg, n  =  20 for 
Heparc-2002, n  =  16 for Heparc-2003). All patients 
continued their daily oral ETV or TDF throughout 
the study. Each patient was assigned to either active 
(ARC-520 injection) or PBO (0.9% normal saline) 
treatment using a block randomization algorithm. 
Final confirmation of eligibility was checked on day 1. 
Other than pharmacists and staff involved in random-
ization, dispensing and preparation of the study drug 
remained blinded.
A subset of 12 patients were to be enrolled into 
each study who were designated pharmacokinetic 
(PK) patients. Blood samples were collected predose 
and at specified times after dosing to determine PK 
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parameters (PK patients only) and pharmacodynamic 
and safety endpoints. Two hours prior to treatment 
administration, all patients were pretreated with oral 
antihistamine.
Visits to the clinical facilities occurred at screening 
and on days 1 (first dose), 2, 15, 29 (second dose), 30, 
43, 57 (third dose), 58, 71, 85 (fourth dose), 86, 99, 
and 113 (end of study [EOS]). Patients randomized 
to the PK portion of the study were to have addi-
tional visits on days 3 and 87. The final follow-up 
visit for patients not enrolled into a planned extension 
study was to occur on day 169. Adverse events (AEs) 
were followed until resolution or grade 1 status was 
achieved, until the condition stabilized, until the event 
was otherwise explained, or until the patient was lost 
to follow-up. The study was performed in accordance 
with the 2008 Declaration of Helsinki(20) and good 
clinical practice guidelines. The study was approved 
by the institutional review board/independent ethics 
committee of the participating institutions. All sub-
jects gave written informed consent before screening. 
Additionally, the sponsor appointed an independent 
data safety monitoring board to provide independent 
oversight of the study and assure patient safety.
paRtICIpaNtS
Potential patients underwent screening to con-
firm eligibility and were randomized during the 60 
days prior to the scheduled dosing date. Patients with 
CHB, 18-75 years in age, were eligible to participate. 
The Heparc-2002 study required a diagnosis of E-neg, 
immune active (indicated by elevated liver enzyme level, 
mentioned below), CHB infection (HBsAg-positive 
for >6 months, confirmed by two assays >6 months 
apart), >2 months of continuous daily oral ETV (0.5 
or 1.0 mg/day) or TDF (300 mg/day), and HBV DNA 
<200 IU/mL at screening. For the Heparc-2003 study, 
E-pos CHB patients with the same inclusion criteria 
were eligible to participate. The full inclusion and exclu-
sion criteria for both Heparc-2002 and Heparc-2003 
studies are listed in Supporting Table S1.
tReatMeNtS
test Formulation
ARC-520 injection was administered by intrave-
nous infusion at a dose of 1.0 or 2.0 mg/kg. Arrowhead 
Pharmaceuticals, Inc. (Pasadena, CA), supplied the 
ARC-520 injection as two sterile 10-mL vials con-
taining ARC-520 active pharmaceutical ingredient 
(API; siRNAs AD0009 and AD0010) and ARC-EX1 
(the delivery excipient). The API is composed of a 
1:1 molar mixture of two synthetic, double-stranded, 
cholesterol-conjugated RNA oligonucleotides. ARC- 
EX1 is a masked, hepatocyte-targeted polymeric 
amine (polymeric amine = L-melittin-derived peptide; 
masking group  =  carboxydimethyl maleic anhydride 
N-acetyl galactosamine melittin-like peptide).(21) 
Prior to dosing subjects, a study pharmacist mixed one 
vial of ARC-EX1 with one vial of API to yield the 
ARC-520 injection.
Reference Formulation
The PBO was normal saline (0.9%).
antihistamine
An oral antihistamine (diphenhydramine 50 mg 
or cetirizine 10 mg or chlorpheniramine 8 mg or 
hydroxyzine 50 mg) was supplied to all patients; all 
antihistamine doses were given at 2 ± 0.5 hours prior 
to study drug or placebo administration.
Patients received four doses of ARC-520 injection 
or PBO every 4 weeks, administered intravenously by 
clinical staff at the infusion rate of 0.4 mL/minute 
concomitantly with 3.6 mL/minute of normal saline. 
The dose administered throughout the trial was based 
on patient weight at screening.
SaFety aSSeSSMeNtS
The safety analysis included all patients who were 
randomized and received study medication. Safety 
measures included (1) AEs, (2) physical examinations 
(3) vital signs (resting heart rate, semisupine systolic/
diastolic blood pressure, respiratory rate, and tempera-
ture); (4) electrocardiogram (ECG) measurements 
(readings taken after the subject was supine for at 
least 3 minutes); (5) clinical laboratory tests (hematol-
ogy, biochemistry, coagulation, and urinalysis); (6) use 
of concomitant medications, and (7) recording reasons 
for treatment discontinuation due to toxicity.
Abnormalities in laboratory findings or other 
assessments that were deemed clinically significant by 
the principal investigators and were initially detected 
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during the study or present at baseline and significantly 
worsened during the study were reported as AEs, 
whether or not they were considered drug-related.
VIRologIC paRaMeteRS
Whole-blood samples were processed for serum and 
samples stored at –80°C until transfer to the bioana-
lytical laboratory. Quantitative HBV serology param-
eters assessed were HBV DNA (Cobas AmpliPrep/
Cobas TaqMan, v2.0; Roche Diagnostics), HBsAg 
(Elecsys HBsAg II quant; Roche Diagnostics), HBeAg 
(Liaison; DiaSorin; E-pos patients only). Qualitative 
assessments also included the presence of antibody 
to HBsAg and antibody to HBeAg (E-pos patients 
only) as well as HBV genotyping and sequencing of 
archival samples, where available.
aDDItIoNal aSSeSSMeNtS
Descriptions of PK, cytokine, and comple-
ment assessments are provided in the Supporting 
Information.
oBJeCtIVeS
The primary objective of the study was to evalu-
ate the depth of HBsAg decline in response to mul-
tiple doses of ARC-520 compared to PBO in patients 
with CHB as a measure of drug activity. Secondary 
objectives were the determination of incidence and 
frequency of AEs possibly or probably related to 
treatment as a measure of safety and tolerability of 
ARC-520 and to evaluate multidose PK of ARC-520 
in patients with HBV when coadministered with a 
fixed dose of ETV or TDF. There were also multiple 
additional exploratory objectives, which were excluded 
from the analysis due to the early termination of the 
studies.
StatIStICal aNalySIS
All study patients who received at least one dose of 
study drug and had valid quantitative HBsAg (qHB-
sAg) values at baseline and at least one time point on 
or after day 15 were included in the intent-to-treat 
(ITT) population. Patients who were randomized to 
either the PBO low-dose or PBO high-dose group 
were pooled into one single PBO group for efficacy 
and safety analyses.
The primary efficacy analysis compared the change 
from baseline to day 113 in the log10 of the qHBsAg 
between each ARC-520 dose group and the pooled 
PBO group in the ITT population. Baseline for effi-
cacy measures was defined as the mean of screening 
(two time points) and day 1 (predose) log qHBsAg 
values, with a minimum of one valid screening and 
a valid day 1 (predose) value required. Change from 
baseline used a restricted maximum likelihood–based 
repeated measures mixed effects model that included 
observations from all regularly scheduled visits for 
each patient. A similar analysis was performed on the 
available quantitative HBeAg data in E-pos patients. 
The HBeAg analysis set included a subset of patients 
with evaluable data as some patients had missing 
HBeAg data due to early termination of the study. A 
detailed description of the statistical methods is pro-
vided in the Supporting Information.
Results
A total of 58 out of 60 and 32 out of 48 planned 
subjects were enrolled and randomized in the 
Heparc-2002 and Heparc-2003 studies, respectively 
(Table 1). A total of 93 and 61 patients were screened 
for Heparc-2002 and Heparc-2003, respectively 
(Supporting Figs. S1 and S2). The demographic data 
for both Heparc-2002 and Heparc-2003 are depicted 
in Table 2.
For Heparc-2002, 9 patients were randomized to 
the PBO low-dose group, 11 to the PBO high-dose 
group, 17 to the ARC-520 injection 1 mg/kg group, 
and 21 to the ARC-520 injection 2  mg/kg group 
(Table 2). Fifty-two of 58 subjects completed the 
study, 4 patients were discontinued due to study ter-
mination by the sponsor, 1 patient withdrew due to 
pregnancy, and 1 patient withdrew consent.
For Heparc-2003, of the 32 patients who enrolled in 
this study, 10 received ARC-520 injection 1.0 mg/kg, 
11 received ARC-520 injection 2.0 mg/kg, 6 received 
PBO low dose, and 5 received PBO high dose 
(Table 2). Twenty-two of 32 randomized subjects 
completed the study, 14 in the ARC-520 injection 
groups and 8 in the PBO groups. Nine of 10 subjects 
who discontinued were due to early study termination 
by the sponsor, and 1 withdrew consent.
Most participants in the Heparc-2002 study and all 
in the Heparc-2003 study were Asian. The remainder 
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of the patients enrolled in the Heparc-2002 study were 
of Caucasian and African descent (Table 2). Median 
age ranged from 37.5 to 48 years across cohorts in 
both studies. HBV genotype information for patients 
in these studies was not available because HBV DNA 
levels were too low for genotyping at screening as all 
patients had been on long-term NUC therapy prior 
to study entry. Historical genotype information was 
not available for any patients either as this is not typ-
ically done as part of standard clinical practice. Based 
on the location of study sites and the ethnicity of 
patients (Table 2), it can be assumed that the majority 
of patients had HBV of either genotype B or C.
VIRologIC ReSpoNSeS
As required per protocol, concomitant NUC med-
ication included either TDF (300 mg) or ETV (0.5 
mg or 1 mg). In all treatment groups, the majority of 
patients received ETV (0.5 mg) as concomitant NUC 
therapy for HBV infection.
All but one E-neg patient entering the Heparc-2002 
study were reported to be NUC-experienced, with a 
mean duration of prior NUC therapy of 5.2-5.4 years 
(Table 3). Heparc-2002 cohorts were well matched 
with regard to their prior years of NUC therapy and 
HBV DNA levels on day 1 and EOS. Only 2 patients 
had measurable HBV DNA levels prior to ARC-520, 
1 PBO patient with a titer of 23 IU/mL at screening 
and 31 IU/mL on day 1 and 1 ARC-520, 1  mg/kg, 
patient with a titer of 28 IU/mL at screening and 
71,665 IU/mL on day 1. The latter patient was 
reported to be on TDF therapy for 5 months prior to 
entering the study. No patients had measurable titers 
at the EOS visit.
E-pos patients entering the Heparc-2003 study 
were all NUC-experienced, with a mean duration 
of prior NUC therapy of 2.8-3.7 years (Table 3). 
Heparc-2003 cohorts were well matched with regard 
to their prior years of NUC therapy and HBV DNA 
levels on day 1 and EOS. Three patients had measur-
able HBV DNA titers, 2 on day 1 and 1 at EOS. All 
reported titers were close to the lower limit of quan-
titation of the assay of 20 IU/mL. Baseline HBsAg 
levels were well matched across cohorts, with mean 
log HBsAg between 2.6 and 3.7 log IU/mL (Table 3); 
and baseline HBsAg was similar in E-neg and E-pos 
patients. Absolute log HBsAg values over the study 
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E-neg patients enrolled in the Heparc-2002 study 
showed a dose-dependent reduction in HBsAg values 
from baseline. The low-dose group had mean reduc-
tions of <0.2 log IU/mL from day 1 through day 113, 
whereas the high-dose group showed mean HBsAg 
reductions of 0.2-0.4 log IU/mL (Fig. 1A). Reductions 
in HBsAg were seen after the first dose, with additional 
reductions after the second dose in the low-dose group 
and after the second and third doses in the high-dose 
group. Nadir for both treatment groups was reached at 
day 99, 15 days after the last dose. A gradual return 
of HBsAg levels was observed after nadir, with both 
groups approaching HBsAg levels observed in the pla-
cebo group by 70 days after nadir. Primary endpoint 







1 mg/kg 2 mg/kg 1 mg/kg 2 mg/kg
NUC-experienced patients 19 of 20 17 of 17 21 of 21 11 of 11 10 of 10 11 of 11
Mean (min, max) years of prior NUC therapy 5.4 (1.5, 8.5) 5.4 (2.5, 7.4) 5.2 (1.4, 8.8) 3.7 (1.4, 7.3) 3.5 (1.2, 5.8) 2.8 (1.0, 6.7)
Baseline log HBsAg
Mean (min, max) Log HBsAg (log IU/mL) 3.3 (2.0, 4.5) 3.2 (0.4, 4.2) 2.6 (0.5, 3.8) 3.7 (2.8, 4.4) 3.3 (2.4, 4.1) 3.3 (2.7, 4.1)
Baseline HBeAg
Mean (min, max) Log HBeAg (log PEIU/mL) N/A N/A N/A 0.7 (–1.1, 1.6) –0.1 (–0.8, 1.0) –0.2 (–1.7, 1.1)
HBV DNA day 1
>20 IU/mL 1 1 0 0 1 1
<20 IU/mL 9 5 4 7 2 5
Not detected 10 10 17 4 7 5
Missing 0 1 0 0 0 0
HBV DNA day 113 EOS
>20 IU/mL 0 0 0 1 0 0
<20 IU/mL 5 6 5 4 2 6
Not detected 12 11 13 4 4 2
Missing/early term 3 0 3 2 4 3
FIg. 1. Mixed effect model repeat measurement analysis of log HBsAg change from baseline to day 113 in the ITT analysis set in the 
Heparc-2002 study. (A) Mean change from baseline over time. (B) Individual and mean log HBsAg change from baseline to day 113. 
*P < 0.05 versus placebo; error bars indicate standard error; baseline = average of screen and day 1 visits.
BA
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analysis was performed at day 113, 30 days after the 
last dose (Supporting Table S2). The high-dose ARC-
520 group showed a highly significant reduction in 
HBsAg (P < 0.0001) compared to placebo, with a mean 
reduction of 0.379 log IU/mL from baseline (Fig. 1B). 
However, the low-dose ARC-520 group was not statis-
tically lower than PBO at day 113 (P = 0.081), with an 
average reduction of 0.157 log IU/mL from baseline.
E-pos patients enrolled in the Heparc-2003 study 
also showed a dose-dependent reduction in HBsAg 
values from baseline. The low-dose group had mean 
reductions of <0.25  log IU/mL from day 1 through 
day 113, whereas the high-dose group showed mean 
HBsAg reductions of 0.2-0.6 log IU/mL (Fig. 2A). 
Reductions in HBsAg were seen after all doses in the 
high-dose group but not in the low-dose group, which 
maintained HBsAg reductions throughout the dosing 
period. Nadir for the low-dose and high-dose treatment 
groups was reached at days 71 and 99, respectively. A 
gradual return of HBsAg levels was observed after 
nadir, with the low-dose group approaching HBsAg 
levels observed in the placebo group by 30 days after 
the last dose. The high-dose group still showed sig-
nificant reductions in HBsAg 70 days after reaching 
nadir. Primary endpoint analysis was performed at day 
113, 30 days after the last dose (Supporting Table S3). 
The high-dose ARC-520 group showed a highly sig-
nificant reduction in HBsAg (P > 0.0001) compared 
to PBO, with a mean reduction of 0.539 log IU/mL 
from baseline (Fig. 2B). However, the low-dose ARC-
520 group was not statistically lower than PBO at 
day 113 (P  =  0.5910), with an average reduction of 
0.143 log IU/mL from baseline.
There were no correlations between baseline 
HBsAg levels and magnitude of HBsAg reduction for 
both E-pos and E-neg patients (Supporting Fig. S5).
FIg. 2. Log HBsAg and HBeAg change from baseline to day 113 in the Heparc-2003 study. (A) Mixed effect model repeat measurement 
analysis of log HBsAg change from baseline to day 113 in the ITT analysis set. (B) Individual and mean log HBsAg change from 
baseline to day 113. (C) Mean log HBeAg change from baseline over time. *P < 0.05 versus placebo; error bars indicate standard error; 
baseline = average of screen and day 1 visits.
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E-pos patients also showed a dose-dependent 
reduction in HBeAg from baseline (Fig. 2C). 
Mean maximum reduction in the low-dose ARC-
520 group was 0.27 log Paul Ehrlich international 
units (PEIUs)/mL on day 43, with HBeAg levels 
gradually returning to baseline after the last dose. 
Mean maximum reduction in the high-dose ARC-
520 group was 0.72 log PEIU/mL on day 43, with 
a sawtooth reduction and recovery observed after 
each dose. Interestingly, mean HBeAg levels were 
gradually decreasing in the placebo group, driven by 
1 patient who had an increase in serum alanine ami-
notransferase from 28 to 64 U/L between days 29 
and 85, concomitant with a 2.2 log PEIU/mL drop 
in HBeAg. All other placebo patients showed min-
imal changes in HBeAg from baseline. Statistical 
analysis showed a significant reduction of HBeAg 
for the high-dose group at 15 days after each dose 
but not at day 113 EOS or other time points. The 
low-dose group showed no significant reduction 
in HBeAg compared to placebo at any time point 
(Fig. 2C; Supporting Table S4).
SaFety aND toleRaBIlIty
Overall, in the Heparc-2002 study, the study treat-
ment was found to be safe and well tolerated. There 
were no deaths in the study, the majority of treat-
ment emergent AEs (TEAEs) were mild, and none 
led to discontinuation from the study treatment or 
the study (Table 4). There were three serious AEs 
(SAEs) in 3 patients reported during the study: 2 
SAEs of pyrexia and 1 SAE of cholangiocarcinoma 
(Table 4). There was one discontinuation due to preg-
nancy. Additionally, there were no significant safety 
issues with regard to vital signs, ECGs, or adverse 
changes in safety laboratory tests.
Similarly, in the Heparc-2003 study, the study 
treatment was safe and well tolerated. There were 
no deaths, pregnancies, SAEs, or severe TEAEs 
reported in this study. The majority of TEAEs were 
mild, and no TEAEs led to discontinuation (Table 4). 
Additionally, there were no significant safety issues 
with regard to vital signs, ECGs, or adverse changes 
in safety laboratory tests.
The SAE of cholangiocarcinoma was reported in a 
61-year-old male patient with a history of CHB, liver 
cirrhosis, osteoarthritis, and hypertension. It was first 
detected during routine ultrasound and confirmed by 
abdominal computed tomographic scan after the last 
dose of ARC-520 and was considered unrelated to 
study drug by the investigator.
The two cases of pyrexia had onset within 1 hour 
of study infusion and were treated successfully with 
acetaminophen. Both patients were kept in the hos-
pital overnight for observation without recurrence of 
fever, causing classification as SAEs considered possi-
bly related.
Because the ARC-EX1 component was derived 
from honey bee venom, allergenicity was measured 
by changes in bee venom immunoglobulin E (IgE) 
levels from predose to EOS. There were no clinically 
significant increases in bee venom–specific IgE levels 
after dose administration in either study. A total of 3 
ARC-520 patients showed an increase in IgE levels 
from predose to postdose, while 2 ARC-520 patients 
showed a decrease. A similar rate of changes was seen 
in PBO patients. Patients experiencing small changes 
in IgE did not demonstrate associated clinical symp-
toms of hypersensitivity.
Discussion
ARC-520 injection was the first RNAi therapeu-
tic targeting HBV to enter clinical testing. It was 
designed to reduce all RNA transcripts derived from 
viral cccDNA, leading to a reduction in viral anti-
gens, as well as HBV DNA. Viral antigens, especially 
HBsAg, have been implicated in the suppression of 
the immune system due to immune exhaustion, lead-
ing to persistence of chronic viral infection. RNAi 
therapy leading to reductions in viral antigens may 
allow for immune reconstitution and functional cure.
ARC-520 has been shown to have a favorable tol-
erability profile in a single-dose study in healthy vol-
unteers.(19) It has also been evaluated in a single-dose 
phase 2 study in patients with CHB.(16) In that study, 
HBsAg was strongly reduced in treatment-naive 
patients positive for HBeAg but was reduced signifi-
cantly less in patients who were E-neg or had received 
long-term therapy with NUCs regardless of HBeAg 
status. This differential response was attributed to the 
finding in chimpanzees that HBsAg was expressed 
not only from the episomal cccDNA minichromo-
some but also from transcripts arising from HBV 
DNA integrated into the host genome, which may 
have been an important or even dominant source 
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of HBsAg in E-neg and Nuc-experienced E-pos 
patients.
Here, we report on two double-blinded, phase 2 
multidose studies of ARC-520 in NUC-experienced, 
E-neg or E-pos patients with CHB in combination 
with TDF or ETV.
The primary objective of the studies was to evaluate 
the depth of HBsAg decline in response to multiple 
doses of ARC-520 compared to PBO as a measure of 
drug activity. The 2 mg/kg high-dose groups met the 
primary endpoint of statistically significant reduction 
in HBsAg compared to PBO 30 days after the fourth 
dose in both E-neg and E-pos patients, while the 
1  mg/kg groups did not. The absolute reductions in 
HBsAg were relatively modest, 0.38 and 0.54 log IU/mL 
for E-neg and E-pos patients, respectively, with 
reductions slightly larger in the E-pos cohort. This 
may be an indication of a larger amount of HBsAg 
expressed from cccDNA in NUC-experienced E-pos 
patients. Overall, reductions in HBsAg were still sig-
nificantly smaller than those observed in NUC-naive, 
E-pos subjects.(16) This is consistent with the mode 
of action and design of ARC-520, which targets all 
transcripts expressed from cccDNA but cannot cleave 
most transcripts resulting from integrated HBV DNA 
due to loss of the target site located in the DR1/DR2 
region of the virus, which is commonly deleted upon 
HBV integration.(16) It is also consistent with reports 
of reductions of cccDNA upon long-term NUC treat-
ment, regardless of HBeAg status.(22) HBsAg lev-
els persisting after multiple doses of ARC-520 may 
therefore represent a “floor” of HBsAg expression that 
cannot be addressed by therapies, including ARC-520, 
that only target cccDNA-derived viral transcripts.
HBsAg reductions persisted for a prolonged period 
of time after multiple doses of ARC-520, approximately 
85 days after the last dose in E-neg and >85 days after 
the last dose in E-pos patients. This prolonged per-
sistence of activity is due to the unique RNAi mecha-
nism in which a small amount of siRNA guide strand 
can persist and be active within the RNA-induced 
silencing complex in the cytoplasm of target cells for 
extended periods of time. A long duration of activity of 
more than 4 weeks has also been demonstrated after a 
single dose of ARC-520 injection in preclinical animal 
studies(21) and in patients with CHB.(23)
ARC-520 was well tolerated in this study, in which 
all patients were pretreated with an oral antihistamine. 
Antihistamine pretreatment was implemented based 
on results from nonclinical and phase 1 studies indi-
cating that ARC-520 could induce histamine release. 
It was subsequently shown that the ARC-EX1 deliv-
ery agent induced histamine release through mast cell 
degranulation.(19) Only two SAEs that were possibly 
related to study drug were reported in both studies, 
both for pyrexia and both occurring shortly after dos-
ing with ARC-520 in two separate patients. Both 
patients went on to receive additional doses of ARC-
520 without subsequent drug-related AEs.
In summary, ARC-520 injection was well tolerated 
in two randomized phase 2 multidose studies in E-pos 
and E-neg, NUC-experienced patients with CHB 
infection. Multiple doses of 2  mg/kg ARC-520 sig-
nificantly reduced HBsAg in both patient groups com-
pared to PBO, and antigen reductions were sustained 
for a long period of time; however, absolute reductions 
were generally moderate. Most likely, the limited phar-
macologic activity was due to the high level of HBsAg 
expression from integrated HBV DNA in these pop-
ulations combined with the inability of ARC-520 to 
target mRNA resulting from integrated HBV DNA. 
This indicates the need for the development of RNAi 
therapeutics that can target all viral transcripts, regard-
less of their origin, as RNAi is the only clinical-stage 
technology currently available that can target HBsAg 
resulting from integrated HBV DNA. Clinical stud-
ies with RNAi molecules that can be subcutaneously 
administered and target viral transcripts from all 
sources, such as ARO-HBV, are now in progress.
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